A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Volenrelaxin (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 12 Feb 2025 Status changed from active, no longer recruiting to discontinued. ( An interim was conducted and after review of available data, including efficacy evaluation of heart failure events, Lilly is terminating the study due to low likelihood of study success for this HFpEF patient population.)
- 13 Dec 2024 Planned End Date changed from 1 Jan 2026 to 1 Jan 2025.
- 13 Dec 2024 Planned primary completion date changed from 1 Nov 2025 to 1 Jan 2025.